Mallinckrodt launches retrospective study for inhaled therapy in COVID-19
Study will collect real-world data on use of INOmax in COVID-19 patients
Read More
Tag: Mallinckrodt
US committee backs terlipressin approval for HRS-1
HRS-1 is an acute and life-threatening syndrome with a survival time of just two weeks if left untreated
Read More
Terlipressin hits phase III endpoint
CONFIRM is the largest-ever prospective study conducted in patients with hepatorenal syndrome type I.
Read More
Mallinckrodt, Silence Theraputics to commercialise RNAi therapeutics
The agreement provides Mallinckrodt with an exclusive worldwide license for C3 (SLN500) – a preclinical asset that targets a specific protein in the complement pathway.
Read More
Mallinckrodt halts mid-stage Acthar trial citing pneumonia risk
ALS is a progressive neurodegenerative disease that affects motor neuron cells in the brain and the spinal cord.
Read More
FDA rejects Mallinckrodt’s abuse-deterrent form of Roxicodone
Mallinckrodt’s SpecGx division has announced the rejection of its abuse-deterrent re-formulation of opioid analgesic Roxicodone by the US Food and Drug Administration (FDA).
Read More
Mallinckrodt to split business
UK-based specialty pharma group Mallinckrodt has unveiled plans to spin-off its specialty generics and active pharmaceutical ingredients business into a new company
Read More
Mallinckrodt’s Niemann-Pick Type C drug fails to hit trial target
UK-based Mallinckrodt has revealed that its experimental therapy for Niemann-Pick Type C failed to hit targets in a recently completed registration trial.
Read More
Mallinckrodt’s stannsoporfin turned away by FDA
US regulators have rejected an application by Mallinckrodt to market stannsoporfin for newborns at risk of jaundice.
Read More
Mallinckrodt snaps up Sucampo for $1.2bn
UK-based pharma Mallinckrodt is buying US biopharma Sucampo Pharmaceuticals for around $1.2 billion.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
